| abstract |
The present disclosure provides for one or more of a stimulant of soluble guanylate cyclase (sGC), a pharmaceutically acceptable salt thereof, and a pharmaceutical formulation or dosage form containing them for treating various CNS diseases. Relates to use in combination with additional drugs. In this regard, increased sGC stimulation or increased concentrations of nitric oxide (NO) or cyclic guanosine 3 ′, 5′-monophosphate (cGMP) or both, or upregulation of the NO pathway is desirable. [Selection figure] None |